Publications and communications of Julien Hanson

Caruso, M., Mazzatenta, D., Asioli, S., Costanza, G., Trivellin, G., Franke, M., Abboud, D., Hanson, J., Veronique Raverot, Pétrossians, P., Beckers, A., Cappa, M., & Daly, A. (2024). Case report: Management of pediatric gigantism caused by the TADopathy, X-linked acrogigantism. Frontiers in Endocrinology, 1-9. doi:10.3389/fendo.2024.1345363

Abboud, D., Abboud, C., Inoue, A., Twizere, J.-C., & Hanson, J. (February 2024). Basal interaction of the orphan receptor GPR101 with arrestins leads to constitutive internalization. Biochemical Pharmacology, 220, 116013. doi:10.1016/j.bcp.2023.116013

Pillaiyar, T., Wozniak, M., Abboud, D., Rasch, A., Liebing, A.-D., Poso, A., Kronenberger, T., Stäubert, C., Laufer, S. A., & Hanson, J. (28 December 2023). Development of Ligands for the Super Conserved Orphan G Protein-Coupled Receptor GPR27 with Improved Efficacy and Potency. Journal of Medicinal Chemistry, 66 (24), 17118 - 17137. doi:10.1021/acs.jmedchem.3c02030

Hanson, J. (2023). Beware the Receptor Variants. Journal of Medicinal Chemistry. doi:10.1021/acs.jmedchem.3c02026

Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Mathie, A. A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Davies, J. A., Abbracchio, M. P., Abraham, G., Agoulnik, A., Alexander, W., Al-Hosaini, K., Bäck, M., Baker, J. G., Barnes, N. M., ... Ye, R. D. (October 2023). The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors. British Journal of Pharmacology, 180 Suppl 2 (S2), 23 - S144. doi:10.1111/bph.16177

Goffin, E., Fraikin, P., Abboud, D., De Tullio, P., Beaufour, C., Botez, I., Hanson, J., Danober, L., Francotte, P., & Pirotte, B. (15 March 2023). New insights in the development of positive allosteric modulators of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors belonging to 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxides: Introduction of (mono/difluoro)methyl groups at the 2-position of the thiadiazine ring. European Journal of Medicinal Chemistry, 250, 115221. doi:10.1016/j.ejmech.2023.115221

Ferraiolo, M., Ponthot, R., Atik, H., Koener, B., Hanson, J., & Hermans, E. (2022). Receptor Density Influences the Recruitment Bias of Aripiprazole and Brexpiprazole at the Dopamine D2L Receptor. Fundamental and Clinical Pharmacology. doi:10.1111/fcp.12812

Bayrak, A., Hanson, J., Laufer, S., & Pillaiyar, T. (2022). Super-conserved receptors expressed in the brain: biology and medicinal chemistry efforts. Future Medicinal Chemistry. doi:10.4155/fmc-2022-0006

Stäubert, C., Wozniak, M., Dupuis, N., Laschet, C., Pillaiyar, T., & Hanson, J. (2022). Superconserved receptors expressed in the brain: Expression, function, motifs and evolution of an orphan receptor family. Pharmacology & Therapeutics, 108217. doi:10.1016/j.pharmthera.2022.108217

Abboud, D., Daly, A., Dupuis, N., Bahri, M. A., Inoue, A., Chevigné, A., Ectors, F., Plenevaux, A., Pirotte, B., Beckers, A., & Hanson, J. (April 2022). Deciphering the role of the GPR101 orphan receptor in growth hormone hypersecretion [Poster presentation]. Keystone Symposia Conference, GPCRs: An Odyssey from Structure, Signaling and Regulation to Therapeutics, Snowbird, United States.

Ferraiolo, M., Atik, H., Ponthot, R., Koener, B., Hanson, J., & Hermans, E. (01 April 2022). Dopamine D2L receptor density influences the recruitment of β-arrestin2 and Gi1 induced by antiparkinsonian drugs. Neuropharmacology, 207 (108942), 1-12. doi:10.1016/j.neuropharm.2022.108942

Schebb, N. H., Kühn, H., Kahnt, A. S., Rund, K. M., O'Donnell, V. B., Flamand, N., Peters-Golden, M., Jakobsson, P.-J., Weylandt, K. H., Rohwer, N., Murphy, R. C., Geisslinger, G., FitzGerald, G. A., Hanson, J., Dahlgren, C., Alnouri, M. W., Offermanns, S., & Steinhilber, D. (02 March 2022). Formation, Signaling and Occurrence of Specialized Pro-Resolving Lipid Mediators-What is the Evidence so far? Frontiers in Pharmacology, 13 (838782), 1-22. doi:10.3389/fphar.2022.838782

Abboud, D., Daly, A., Dupuis, N., Bahri, M. A., Inoue, A., Chevigné, A., Ectors, F., Plenevaux, A., Pirotte, B., Beckers, A., & Hanson, J. (February 2022). Deciphering the role of the GPR101 orphan receptor in growth hormone hypersecretion [Paper presentation]. CIRM day, Liege, Belgium.

D'Uonnolo, G., Reynders, N., Meyrath, M., Abboud, D., Uchański, T., Laeremans, T., Volkman, B. F., Janji, B., Hanson, J., Szpakowska, M., & Chevigné, A. (2022). The Extended N-Terminal Domain Confers Atypical Chemokine Receptor Properties to CXCR3-B. Frontiers in Immunology, 13, 868579. doi:10.3389/fimmu.2022.868579

Dam, J., Hanson, J., & Szpakowska, M. (2022). Editorial: Emerging receptors as new targets in health and disease. Frontiers in Endocrinology, 13, 1073794. doi:10.3389/fendo.2022.1073794

Pillaiyar, T., Rosato, F., Wozniak, M., Blavier, J., Charles, M., Laschet, C., Kronenberger, T., Müller, C. E., & Hanson, J. (05 December 2021). Structure-activity relationships of agonists for the orphan G protein-coupled receptor GPR27. European Journal of Medicinal Chemistry, 225, 113777. doi:10.1016/j.ejmech.2021.113777

Abboud, D., Daly, A., Dupuis, N., Bahri, M. A., Inoue, A., Chevigné, A., Ectors, F., Plenevaux, A., Pirotte, B., BECKERS, A., & Hanson, J. (October 2021). Deciphering the role of the GPR101 orphan receptor in growth hormone hypersecretion [Poster presentation]. 5th ERNEST meeting, Bari, Italy.

Abboud, D., Daly, A., Dupuis, N., Bahri, M. A., Inoue, A., Chevigné, A., Ectors, F., Plenevaux, A., Pirotte, B., BECKERS, A., & Hanson, J. (July 2021). GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of Gs and Gq/11 [Poster presentation]. 1st Transatlantic ECI GPCR symposium.

Laschet, C., & Hanson, J. (2021). Nanoluciferase-based complementation assay to detect GPCR-G protein interaction. In S. Martins & D. Prazeres, G Protein-Coupled Receptor Screening Assays - Methods in Molecular Biology (pp. 149-157). Clifton, United States - New Jersey: Humana Press. doi:10.1007/978-1-0716-1221-7_10

Abboud, D., Daly, A., Dupuis, N., Bahri, M. A., Inoue, A., Chevigné, A., Ectors, F., Plenevaux, A., Pirotte, B., BECKERS, A., & Hanson, J. (May 2021). GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of Gs and Gq/11 [Paper presentation]. FASEB, The Growth Hormone (GH)/ Prolactin (PRL) Family in Biology & Disease Conference.

Abboud, D., Daly, A., Dupuis, N., Bahri, M. A., Inoue, A., Chevigné, A., Ectors, F., Plenevaux, A., Pirotte, B., BECKERS, A., & Hanson, J. (April 2021). GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of Gs and Gq/11 [Paper presentation]. Belgian Society of Physiology and Pharmacology.

Abboud, D., Daly, A., Dupuis, N., Bahri, M. A., Inoue, A., Chevigné, A., Ectors, F., Plenevaux, A., Pirotte, B., Beckers, A., & Hanson, J. (April 2021). GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of Gs and Gq/11 [Paper presentation]. 4th ERNEST meeting.

Abboud, D., Daly, A., Dupuis, N., Bahri, M. A., Inoue, A., Chevigné, A., Ectors, F., Plenevaux, A., Pirotte, B., BECKERS, A., & Hanson, J. (April 2021). GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of Gs and Gq/11 [Poster presentation]. American Society for Pharmacology and Experimental Therapeutics (ASPET), GPCR colloquium.

Ferraiolo, M., Beckers, P., Marquet, N., Roumain, M., Ruiz, L., Dupuis, N., Hanson, J., & Hermans, E. (February 2021). β-arrestin2 recruitment at the β2 adrenergic receptor: a luciferase complementation assay adapted for undergraduate training in pharmacology. Pharmacology Research and Perspectives, 9 (1). doi:10.1002/prp2.706

Alexander, S. P., Christopoulos, A., Davenport, A. P., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Melmed, S., Michel, M. C., Miller, L. J., Mitolo, V., Mouillac, B., Müller, C. E., Murphy, P., Nahon, J.-L., ... McArdle, C. A. (2021). THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors. British Journal of Pharmacology, 178 Suppl 1, 27-S156. doi:10.1111/bph.15538

Kerselidou, D., Dohai, B. S., Nelson, D. R., Daakour, S., De Cock, N., Hassoun, Z. E. O., Kim, D.-K., Olivet, J., El Assal, D. C., Jaiswal, A., Alzahmi, A., Saha, D., Pain, C., Matthijssens, F., Lemaitre, P., Herfs, M., Chapuis, J., Ghesquiere, B., Vertommen, D., ... Twizere, J.-C. (2021). Alternative glycosylation controls endoplasmic reticulum dynamics and tubular extension in mammalian cells. Science Advances, 7 (19). doi:10.1126/sciadv.abe8349

Abboud, D., Daly, A., Dupuis, N., Bahri, M. A., Inoue, A., Chevigné, A., Ectors, F., Plenevaux, A., Pirotte, B., Beckers, A., & Hanson, J. (November 2020). GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of Gs and Gq/11 [Paper presentation]. GDR3545.

Abboud, D., Daly, A., Dupuis, N., Bahri, M. A., Inoue, A., Chevigné, A., Ectors, F., Plenevaux, A., Pirotte, B., Beckers, A., & Hanson, J. (21 September 2020). GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of Gs and Gq/11. Nature Communications, 11 (1), 4752. doi:10.1038/s41467-020-18500-x

Abboud, D., Daly, A., Dupuis, N., Bahri, M. A., Inoue, A., Chevigné, A., Ectors, F., Plenevaux, A., Pirotte, B., BECKERS, A., & Hanson, J. (2020). GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of Gs and Gq/11 [Paper presentation]. 9TH GDR3545 GPCR INTERNATIONAL MEETING.

Hanson, J. (2020). Nouvelles cibles et perspectives thérapeutiques. Vers une médecine de précision. Revue Médicale de Liège, 75 (5-6), 460-465.

Abboud, D., Daly, A., Dupuis, N., Pirotte, B., BECKERS, A., & Hanson, J. (December 2019). GPR101 orphan receptor in XLAG syndrome [Paper presentation]. CIRM day.

Alexander, Christopoulos, A., Davenport, A., Kelly, E., Mathie, A., Peters, J., Veale, E., Armstrong, J., Faccenda, E., Harding, S., Pawson, A., Sharman, J., Southan, C., Davies, J., Hanson, J., & CGTP Collaborators. (December 2019). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology, 176 (Suppl 1), 21-S141. doi:10.1111/bph.14748

Vandevoorde, S., Daly, A., Hanson, J., & Beckers, A. (December 2019). Somatostatin Analogue Resistance in McCune-Albright Syndrome [Poster presentation]. 2nd CIRM Scientific Day, Liege, Belgium.

Franssen, D., Lopez Rodriguez, D., Dupuis, N., GERARD, A., Hanson, J., Bourguignon, J.-P., & Parent, A.-S. (September 2019). GPR151, a new regulator of GnRH neurons [Poster presentation]. The European Centre for Reproductive Endocrinology (EUCRE).

Balthazart, J., Blanpain, C., Bureau, F., Cani, P., Chariot, A., Drion, P., Engel, V., Hanson, J., de Kerchove d'Exaerde, A., Malgrange, B., Muraille, E., Nguyen, L., Servais, O., Seutin, V., & Tissir, F. (2019). L’expérimentation animale : toujours une nécessité pour la santé animale et humaine. Le Soir.

Abboud, D., Daly, A., Dupuis, N., Pirotte, B., BECKERS, A., & Hanson, J. (July 2019). Pharmacology of GPR101 orphan receptor [Paper presentation]. Transardennaise de l’hypophyse.

Reynders, N., Abboud, D., Baragli, A., Noman, M. Z., Rogister, B., Niclou, S., Heveker, N., Janji, B., Hanson, J., Szpakowska, M., & Chevigné, A. (18 June 2019). The Distinct Roles of CXCR3 Variants and Their Ligands in the Tumor Microenvironment. Cells, 8 (6).

Abboud, D., Daly, A., Dupuis, N., Pirotte, B., BECKERS, A., & Hanson, J. (May 2019). GPR101 orphan receptor in XLAG syndrome [Paper presentation]. Belgian Society of Physiology and Pharmacology.

Vandevoorde, S., Abboud, D., Laschet, C., Daly, A., Hanson, J., & Beckers, A. (May 2019). SOMATOSTATIN ANALOGUE RESISTANCE IN X-LAG SYNDROME - IDENTIFICATION OF THE UNDERLYING MECHANISMS [Poster presentation]. Spring meeting 2019 Belgian Society of Physiology and Pharmacology, Bruxelles, Belgium.

Laschet, C., Dupuis, N., & Hanson, J. (15 March 2019). A dynamic and screening-compatible nanoluciferase-based complementation assay enables profiling of individual GPCR-G protein interactions. Journal of Biological Chemistry, 294 (11), 4079-4090. doi:10.1074/jbc.RA118.006231

Abboud, D., Daly, A., Dupuis, N., Pirotte, B., BECKERS, A., & Hanson, J. (December 2018). GPR101 orphan receptor in XLAG syndrome [Paper presentation]. CIRM day.

Beckers, A., PETROSSIANS, P., Hanson, J., & Daly, A. (25 October 2018). The causes and consequences of pituitary gigantism. Nature Reviews. Endocrinology, 14, 705-720. doi:10.1038/s41574-018-0114-1

Farcas, E., Servais, A.-C., Hanson, J., Pochet, L., & Fillet, M. (10 September 2018). Partial filling capillary electrophoretic mobility shift competition assay: a versatile and reliable tool for the assessment of weak biomolecular interactions [Paper presentation]. The 11th International Symposium on Drug Analysis and the 29th International Symposium on Pharmaceutical and Biomedical Analysis, Leuven, Belgium.

Abboud, D., Daly, A., Laschet, C., Pirotte, B., BECKERS, A., & Hanson, J. (05 July 2018). GPR101 orphan receptor: a novel cause of growth hormone deregulation [Paper presentation]. World Congress of Basic and Clinical Pharmacology WCP 2018- IUPHAR, Kyoto, Japan.

Abboud, D., Daly, A., Dupuis, N., Pirotte, B., BECKERS, A., & Hanson, J. (July 2018). The orphan receptor GPR101 as a novel cause of growth hormone deregulation [Poster presentation]. 18th International Union of Basic and Clinical Pharmacology (IUPHAR) congress.

Laschet, C., Dupuis, N., & Hanson, J. (July 2018). The G Protein-Coupled Receptors Deorphanization Landscape. Biochemical Pharmacology, 153, 62-74. doi:10.1016/j.bcp.2018.02.016

Meyrath, M. M. R., Szpakowska, M., Reynders, N., Counson, M., Hanson, J., Steyaert, J., & Chevigné, A. (2018). Atypical Ligand Binding and Activation Modes of ACKR3/CXCR7 [Paper presentation]. Gordon Research Seminars, Chemotactic cytokines.

Meyrath, M. M. R., Szpakowska, M., Reynders, N., Counson, M., Hanson, J., Steyaert, J., & Chevigné, A. (28 May 2018). Distinct binding and activation modes of the atypical chemokine receptor ACKR3/CXCR7 by chemokine and endogenous non-chemokine agonists [Poster presentation]. EDT immunology day “Innate immunity in health and disease”, Liege, Sart Tilman, Belgium.

Szpakowska, M., Nevins, A. M., Meyrath, M. M. R., Rhainds, D., D'huys, T., Guité-Vinet, F., Dupuis, N., Gauthier, P.-A., Counson, M., Kleist, A., St-Onge, G., Hanson, J., Schols, D., Volkman, B., Heveker, N., & Chevigné, A. (May 2018). Different contribution of chemokine N-terminal features attest a different ligand binding mode and a bias towards activation of the atypical chemokine receptor ACKR3/CXCR7 compared to CXCR4 and CXCR3. British Journal of Pharmacology, 175 (9), 1419-1438. doi:10.1111/bph.14132

Vandevoorde, S., Laschet, C., Dupuis, N., & Hanson, J. (May 2018). Phoenixine-20-amide does not bind heterologously expressed GPR173 [Poster presentation]. Spring meeting 2018 Belgian Society of Physiology and Pharmacology, Bruxelles, Belgium.

Bakker, J., Balthazart, J., Baron, F., Beguin, Y., Bettendorff, L., Blanpain, C., Bureau, F., Caers, J., Cani, P., Cataldo, D., Cornil, C., Clercx, C., Cloots, R., Colige, A., Daube, G., De Backer, O., de Kerchove d'Exaerde, A., Desmecht, D., Desmet, C., ... Wittamer, V. (2018). La souris, le patient, et le faux expert. Décryptage d'une mystification. Le Vif. L'Express.

Muraille, E., de Kerchove d'Exaerde, A., Blanpain, C., Vassart, G., Parmentier, M., Moser, M., Oberdan, L., Vanderhaegen, P., Vanduffel, W., Vogels, R., Tissir, F., Bureau, F., Hanson, J., Drion, P., Georges, M., Seutin, V., Ris, L., & De Backer, O. (2018). L'expérimentation animale ne se fait pas en dehors de tout contrôle (OPINION). La Libre Belgique.

Courtois, A., Makrygiannis, G., CHERAMY-BIEN, J.-P., Purnelle, A., Pirotte, B., Dogné, J.-M., Hanson, J., Defraigne, J.-O., Drion, P., & SAKALIHASAN, N. (2018). Therapeutic Applications of Prostaglandins and Thromboxane A2 Inhibitors in Abdominal Aortic Aneurysms. Current Drug Targets. doi:10.2174/1389450119666171227224314

Drapier, T., Geubelle, P., Bouckaert, C., Nielsen, L., Laulumaa, S., Goffin, E., Dilly, S. A., Francotte, P., Hanson, J., Pochet, L., Kastrup, J., & Pirotte, B. (2018). Enhancing Action of Positive Allosteric Modulators through the Design of Dimeric Compounds. Journal of Medicinal Chemistry. doi:10.1021/acs.jmedchem.8b00250

Farcas, E., Hanson, J., Pochet, L., & Fillet, M. (2018). Capillary electrophoretic mobility shift displacement assay for the assessment of weak drug-protein interactions. Analytica Chimica Acta. doi:10.1016/j.aca.2018.06.024

Goffin, E.* , Drapier, T.* , Probst Larsen, A., Geubelle, P., Ptak, C. P., Laulumaa, S., Rovinskaja, K., Gilissen, J., De Tullio, P., Olsen, L., Frydenvang, K., Pirotte, B., Hanson, J., Oswald, R. E., Sandholm Kastrup, J., & Francotte, P. (2018). 7‐Phenoxy-Substituted 3,4-Dihydro‐2H‐1,2,4-benzothiadiazine 1,1- Dioxides as Positive Allosteric Modulators of α‐Amino-3-hydroxy-5- methyl-4-isoxazolepropionic Acid (AMPA) Receptors with Nanomolar Potency. Journal of Medicinal Chemistry, 61, 251-264. doi:10.1021/acs.jmedchem.7b01323
* These authors have contributed equally to this work.

Szpakowska, M., Meyrath, M. M. R., Reynders, N., Counson, M., Hanson, J., Steyaert, J., & Chevigné, A. (2018). Mutational analysis of the extracellular disulphide bridges of the atypical chemokine receptor ACKR3/CXCR7 uncovers multiple binding and activation modes for its chemokine and endogenous non-chemokine agonists. Biochemical Pharmacology, 153, 299-309. doi:10.1016/j.bcp.2018.03.007

Alexander, S., Kelly, E., Marrion, N., Peters, J., Faccenda, E., Harding SD, Pawson, A., Sharman, J., Southan, C., Buneman, O., Cidlowski, J., Christopoulos, A., Davenport, A., Fabbro, D., Spedding, M., Striessing, J., Davies, J., Hanson, J., & CGTP Collaborators. (December 2017). THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview. British Journal of Pharmacology, 174 (Suppl 1), 1-S16. doi:10.1111/bph.13882

Amorim, C., Andris, F., Arckens, L., Arnould, T., Aron, S., Bakker, J., Balligand, M., Balthazart, J., Baron, F., Beck, B., Beguin, Y., Behets, C., Bellefroid, E., Bertrand, L., Bettendorff, L., Bindels, L., Blankert, B., Blanpain, C., Bondue, A., ... Wittamer, V. (2017). L’expérimentation animale reste indispensable (OPINION). La Libre Belgique.

Geubelle, P., Gilissen, J., Laschet, C., Dilly, S., Huart, J., Jouret, F., Pirotte, B., & Hanson, J. (13 September 2017). Development of original ligands for SUCNR1 [Poster presentation]. International Symposium on GPCRs and G-proteins, Bonn, Königswinter, Germany.

Laschet, C., Dupuis, N., Geubelle, P., Abboud, D., & Hanson, J. (September 2017). Targeted mutagenesis of orphan GPCRs of the SREB family [Poster presentation]. International Symposium on GPCRs and G-proteins, Bonn, Germany.

Abboud, D., Daly, A., Laschet, C., Pirotte, B., BECKERS, A., & Hanson, J. (07 July 2017). Pharmacology of GPR101 [Paper presentation]. Transardennaise de l'hypophyse, Liège, Belgium.

Dupuis, N., Laschet, C., Franssen, D., Martyna, S., Gilissen, J., Geubelle, P., Soni, A., Parent, A.-S., Pirotte, B., Chevigné, A., Twizere, J.-C., & Hanson, J. (01 June 2017). Activation of the orphan G protein-coupled receptor GPR27 by surrogate ligands promotes β-arrestin 2 recruitment. Molecular Pharmacology, 91 (6), 595-608. doi:10.1124/mol.116.107714

Abboud, D., Daly, A., Dupuis, N., Laschet, C., Geubelle, P., Pirotte, B., BECKERS, A., & Hanson, J. (May 2017). GPR101 orphan GPCR: a novel cause of growth hormone deregulation [Poster presentation]. 19th European Congress of Endocrinology, Lisbon, Portugal.

Geubelle, P., Gilissen, J., Dilly, S., POMA, L., Dupuis, N., Laschet, C., Abboud, D., Inoue, A., Jouret, F., Pirotte, B., & Hanson, J. (May 2017). Identification and pharmacological characterization of succinate receptor agonists. British Journal of Pharmacology, 174 (9), 796-808. doi:10.1111/bph.13738

Franssen, D., Dupuis, N., Lopez Rodriguez, D., GERARD, A., Hanson, J., Bourguignon, J.-P., & Parent, A.-S. (04 April 2017). Alteration of the neuroendocrine control of puberty after postnatal exposure to Bisphenol A and involvement of GPR151, a potential new regulator of the GnRH network [Paper presentation]. ENDO2017.

Abboud, D., Daly, A., Dupuis, N., Laschet, C., Geubelle, P., Pirotte, B., BECKERS, A., & Hanson, J. (April 2017). GPR101 orphan GPCR: a novel cause of growth hormone deregulation [Poster presentation]. Belgian Society of Physiology and Pharmacology, Bruxelles, Belgium.

Abboud, D., & Hanson, J. (April 2017). Chemokine neutralization as an innovative therapeutic strategy for atopic dermatitis. Drug Discovery Today, 22 (4), 702-7011. doi:10.1016/j.drudis.2016.11.023

Franssen, D., Dupuis, N., Lopez Rodriguez, D., Hanson, J., GERARD, A., Bourguignon, J.-P., & Parent, A.-S. (March 2017). Postnatal exposure to BPA disturbs neuroendocrine control of puberty without affecting Kiss1 system but involves GPR151, a potential new regulator of the GnRH network [Poster presentation]. The 3rd World Conference on Kisspeptin.

Farcas, E., Bouckaert, C., Servais, A.-C., Hanson, J., Pochet, L., & Fillet, M. (2017). Partial filling affinity capillary electrophoresis as a useful tool for fragment-based drug discovery: A proof of concept on thrombin. Analytica Chimica Acta, 984, 211-222. doi:10.1016/j.aca.2017.06.035

Abboud, D., Dupuis, N., Laschet, C., Geubelle, P., Pirotte, B., & Hanson, J. (November 2016). GPR101 orphan GPCR: a novel cause of growth hormone deregulation [Poster presentation]. Fifth annual meeting of the CNRS GDR-3545, G Protein-coupled Receptors: from Physiology to Drugs (RCPG-Physio-Med), Tours, France.

Franssen, D., Dupuis, N., Lopez Rodriguez, D., GERARD, A., Hanson, J., Bourguignon, J.-P., & Parent, A.-S. (October 2016). Identification of an orphan GPCR, GPR151, as a target of BPA exposure and a potential actor of the GnRH network [Paper presentation]. 41e colloque de la société de Neuroendocrinologie.

Dupuis, N., Franssen, D., Laschet, C., Geubelle, P., Soni, A., Abboud, D., Twizere, J.-C., Pirotte, B., & Hanson, J. (26 September 2016). Small molecule ligands for the orphan GPR27 [Poster presentation]. GLISTEN meeting 2016 in Prague.

Laschet, C., Dupuis, N., Soni, A., Geubelle, P., Abboud, D., & Hanson, J. (September 2016). Targeted mutagenesis of orphan GPCRs of the SREB family [Poster presentation]. GLISTEN 2016 in Prague.

Szpakowska, M., Dupuis, N., Baragli, A., Counson, M., Hanson, J., Piette, J., & Chevigné, A. (15 August 2016). Human herpesvirus 8-encoded chemokine vCCL2/vMIP-II is an agonist of the atypical chemokine receptor ACKR3/CXCR7. Biochemical Pharmacology, 114, 14-21. doi:10.1016/j.bcp.2016.05.012

Drapier, T., Geubelle, P., Bouckaert, C., Goffin, E., Dilly, S., Hanson, J., Pochet, L., Kastrup, J. S., Francotte, P., & Pirotte, B. (26 May 2016). DESIGN OF HIGH-AFFINITY LIGANDS FOR THE BENZOTHIADIAZINE ALLOSTERIC BINDING SITE OF THE AMPA RECEPTORS [Poster presentation]. JFB 2016 : 30èmes Journées Franco-Belges de Pharmacochimie 25-27 May 2016 Amboise (France), Amboise, France.

Geubelle, P., Gilissen, J., Dilly, S., Jouret, F., Pirotte, B., & Hanson, J. (26 May 2016). Development of original ligands for SUCNR1 [Poster presentation]. 30èmes JFB de Pharmacochimie, Amboise, France.

Hanson, J. (18 April 2016). A forskolin free method for measuring cAMP modulation by Gi coupled receptors [Paper presentation]. Discover Glo Tour.

Franssen, D., Dupuis, N., GERARD, A., Hennuy, B., Hanson, J., Bourguinon, J.-P., & Parent, A.-S. (06 March 2016). Disruption of GnRH secretion in peripubertal female rat after early postnatal exposure to Bisphenol A and involvement of GPR151, a potential new GnRH regulator [Poster presentation]. GnRH COST meeting.

Dupuis, N., Gilissen, J., Derj, A., Soni, A., Geubelle, P., Laschet, C., Piron, C., Twizere, J.-C., Pirotte, B., & Hanson, J. (25 January 2016). Identification of small molecule ligands for the orphan GPCR GPR27 [Poster presentation]. GIGA-DAY 2016.

Geubelle, P., Gilissen, J., Dupuis, N., Derj, A., Laschet, C., Soni, A., Pirotte, B., & Hanson, J. (25 January 2016). Design, synthesis and identification of ligands for SUCNR1 and GPR22 [Paper presentation]. 2016 GIGA Day - Signal transduction pathways in health and disease, Liège, Belgium.

Laschet, C., Dupuis, N., Derj, A., Gilissen, J., Geubelle, P., Soni, A., Pirotte, B., & Hanson, J. (25 January 2016). Targeted and random mutagenesis of orphan GPCRs of the SREB family [Poster presentation]. GIGA-Day.

Gilissen, J., Jouret, F., Pirotte, B., & Hanson, J. (2016). Insight into SUCNR1 (GPR91) structure and function. Pharmacology and Therapeutics. doi:10.1016/j.pharmthera.2016.01.008

Hanson, J., & Chevigné, A. (2016). GPCRs in immunity: atypical receptors and novel concepts. Biochemical Pharmacology. doi:10.1016/j.bcp.2016.06.017

Geubelle, P., Gilissen, J., Dupuis, N., Derj, A., Laschet, C., Soni, A., Pirotte, B., & Hanson, J. (05 June 2015). Identification, Design and Evaluation of Pharmacological tools for the orphan GPCR GPR22 [Paper presentation]. 29ème Journées Franco-Belge de Pharmacochimie, Spa, Belgium.

Drapier, T., Francotte, P., Pirotte, B., Goffin, E. (Other coll.), Hanson, J. (Other coll.), Dilly, S. (Other coll.), & Kastrup, J. (Other coll.). (04 June 2015). Design, synthesis and pharmacological evaluation of dimeric ligands for the benzothiadiazine dioxide allosteric binding site of the AMPA receptors [Paper presentation]. 29ème Journées Franco-Belge de Pharmacochimie, Spa, Belgium.

Dupuis, N., Gilissen, J., Derj, A., Laschet, C., Geubelle, P., Soni, A., Piron, C., Twizere, J.-C., Pirotte, B., & Hanson, J. (27 January 2015). ßarrestin coupling of the orphan GPCR GPR27 [Poster presentation]. GIGA-day 2015, Liege, Belgium.

Geubelle, P., Gilissen, J., Dupuis, N., Derj, A., Laschet, C., Soni, A., Pirotte, B., & Hanson, J. (27 January 2015). Identification, Design and Evaluation of Pharmacological tools for the orphan GPCR GPR22 [Poster presentation]. 2015 GIGA Day: Current Advances in Medical Genetics and Genomics, Liège, Belgium.

Franssen, D., Dupuis, N., GERARD, A., HENNUY, B., Hanson, J., Bourguignon, J.-P., & Parent, A.-S. (2015). Disruption of Gonadotropin-Releasing Hormone secretion in peripubertal female rat after early postnatal exposure to Bisphenol A and involvement of GPR151, a potential new Gonadotropin-Releasing Hormone regulator [Poster presentation]. Society for Neurosciences (SFN).

Franssen, D., Dupuis, N., GERARD, A., HENNUY, B., Hanson, J., Parent, A.-S., & Bourguignon, J.-P. (2015). Alteration of the neuroendocrine control of puberty after early postnatal exposure to Bisphenol A and involvement of a potential new regulator of GnRH network GPR151 [Poster presentation]. BSN-SNE joint meeting.

Gilissen, J., Geubelle, P., Dupuis, N., Laschet, C., Pirotte, B., & Hanson, J. (2015). Forskolin-free cAMP assay for Gi-coupled receptors. Biochemical Pharmacology. doi:10.1016/j.bcp.2015.09.010

Geubelle, P., Gilissen, J., Dupuis, N., Derj, A., Laschet, C., Soni, A., Pirotte, B., & Hanson, J. (21 November 2014). Identification, Design and Evaluation of Pharmacological tools for the orphan GPCR GPR22 [Poster presentation]. MedChem 2014 New Vistas in GPCR Research: the Dawn of an Exciting Drug Discovery Era?, Braine-L'Alleud, Belgium.

Gilissen, J., Dupuis, N., Derj, A., Soni, A., Dilly, S., Pirotte, B., & Hanson, J. (21 November 2014). Identification of modulators for SUCNR1 by screening of a SOSA library with a bioluminescent cAMP assay [Paper presentation]. MedChem 2014, Braine-L'alleud (UCB), Belgium.

Laschet, C., Dupuis, N., Derj, A., Gilissen, J., Geubelle, P., Soni, A., Pirotte, B., & Hanson, J. (21 November 2014). Understanding the pharmacology and signaling pathways of the orphan G protein coupled receptor GPR85/SREB2 [Poster presentation]. Annual one-day meeting on medicinal chemistry.

Dupuis, N., Gilissen, J., Derj, A., Laschet, C., Geubelle, P., Soni, A., Twizere, J.-C., Pirotte, B., & Hanson, J. (October 2014). Identifying ligands for orphan receptors: test screening of a SOSA library with a complementation assay for orphan GPCR GPR27 [Poster presentation]. third annual meeting of the GDR3545, Montpellier, France.

Dupuis, N., Gilissen, J., Derj, A., Soni, A., Twizere, J.-C., Pirotte, B., & Hanson, J. (16 July 2014). Ligand-independent Identification of orphan GPCR Signaling pathways [Paper presentation]. World Congress of basic & clinical Pharmacology, Cape Town, South Africa.

Dupuis, N., Gilissen, J., Derj, A., Soni, A., Twizere, J.-C., Pirotte, B., & Hanson, J. (05 June 2014). LIGAND-INDEPENDENT IDENTIFICATION OF ORPHAN GPCR ARRESTIN BINDING [Poster presentation]. 23èmes Journées franco-belges de Pharmacochimie, Metz, France.

Drapier, T., Goffin, E., Hanson, J., Dilly, S., Francotte, P., Kastrup, J., & Pirotte, B. (June 2014). DESIGN OF HIGH-AFFINITY LIGANDS FOR THE BENZOTHIADIAZINE ALLOSTERIC BINDING SITE OF THE AMPA RECEPTORS [Poster presentation]. 28èmes Journées franco-belges de Pharmacochimie, Metz, France.

Dupuis, N., Gilissen, J., Derj, A., Soni, A., Twizere, J.-C., Pirotte, B., & Hanson, J. (04 April 2014). Ligand-independent Identification of orphan GPR27 Signaling pathways [Poster presentation]. Physphar 2014.

Derj, A., Dupuis, N., Gilissen, J., Soni, A., Pirotte, B., Chevigné, A., & Hanson, J. (27 January 2014). Unraveling the signaling and dimerization properties of CXCR3 isoforms and their interplay with CXCR7 in the context of glioblastoma pathology [Poster presentation]. GIGA Day 2014, Liège, Belgium.

Dupuis, N., Gilissen, J., Derj, A., Soni, A., Twizere, J.-C., Pirotte, B., & Hanson, J. (14 January 2014). Development of a luciferase complementation assay for ligand screening on orphan GPCR GPR27 [Poster presentation]. GIGA-DAY 2014.

Dupuis, N., Gilissen, J., Twizere, J.-C., Pirotte, B., & Hanson, J. (18 October 2013). Development of an original β-arrestin complementation assay for orphan GPCR GPR27(SREB1) ligand and signaling pathways determination [Poster presentation]. Autumn Meeting of Belgian Society of Physiology and Pharmacology.

Bambi Nyanguile, S.-M., Hanson, J., OOMS, A., Alpan, L., Kolh, P., dogné, J.-M., & Pirotte, B. (July 2013). Synthesis and pharmacological evaluation of 2-aryloxy/arylamino-5-cyanobenzenesulfonylureas as novel thromboxane A2 receptor antagonists. European Journal of Medicinal Chemistry, 65, 32-40. doi:10.1016/j.ejmech.2013.04.033

Dupuis, N., Gilissen, J., Pirotte, B., & Hanson, J. (06 June 2013). Identification of chemical probes and signaling pathways for the orphan GPCR GPR27 [Poster presentation]. 27èmes Journées franco-belges de Pharmacochimie & 21èmes Conférences européennes du GP2A, Lille, France.

Dupuis, N., Gilissen, J., Pirotte, B., & Hanson, J. (28 January 2013). Chemical probes and signaling pathways for the orphan GPCR GPR27 [Poster presentation]. Giga-Day 2013.

Gilissen, J., Pirotte, B., Hanson, J., & Dupuis, N. (Other coll.). (28 January 2013). Pharmacological evaluation of succinic acid receptor (SUCNR1) modulators [Poster presentation]. GIGA Day 2013.

Hanson, J., Ferreiros, N., Pirotte, B., Geisslinger, G., & Offermanns, S. (2013). Heterologously expressed formyl peptide receptor 2 (FPR2/ALX) does not respond to lipoxin A4. Biochemical Pharmacology, 85, 1795-1802. doi:10.1016/j.bcp.2013.04.019

Gilissen, J., Pirotte, B., Hanson, J., & Dupuis, N. (Other coll.). (30 November 2012). Synthesis and pharmacological evaluation of succinic acid receptor (SUCNR1) small molecule modulators [Poster presentation]. MedChem 2012 - From Rapid Dissociation to Irreversible Inhibition - Optimisation of Drug-Target Residence Time.

Bambi Nyanguile, S.-M., Hanson, J., Dogné, J.-M., & Pirotte, B. (August 2012). Development of original 2-aryloxy/arylamino-5-cyanobenzenesulfonylureas as thromboxane A2 receptor antagonists [Poster presentation]. 19th EuroQSAR, VIENNE, Austria.

Bambi Nyanguile, S.-M., Hanson, J., Dogné, J.-M., & Pirotte, B. (May 2012). Development of original diversely substituted benzenesulfonylureas as thromboxane A2 receptor antagonists [Poster presentation]. 26 eme journées Francobelges de Pharmacochimie, Orléans, France.

Gilissen, J., Pirotte, B., & Hanson, J. (2012). Pharmacological evaluation of succinic acid receptor (SUCNR1) small molecule modulators with an intracellular calcium biosensor [Poster presentation]. Giga Day.

Gilissen, J., Pirotte, B., & Hanson, J. (2012). Identification by a SOSA library screening and structure-activity relationships of succinic acid receptor (SUCNR1 or GPR91) agonist [Paper presentation]. 26èmes Journées Franco-belges de Pharmacochimie.

Gilissen, J., Pirotte, B., & Hanson, J. (2012). Design, synthesis and structure-activity relationship study of succinic acid receptor (SUCNR1) modulators [Paper presentation]. Forum des sciences pharmaceutiques.

Hanson, J., Gille, A., & Offermanns, S. (2012). Role of HCA₂ (GPR109A) in nicotinic acid and fumaric acid ester-induced effects on the skin. Pharmacology and Therapeutics. doi:10.1016/j.pharmthera.2012.06.003

Cherdon, C., Rolin, S., Hanson, J., OOMS, A., de Leval, L., Drion, P., michiels, C., Pirotte, B., Mullier, F., SakalihasanN, N., DEFRAIGNE, J., & Dogné, J.-M. (2011). BM-573 INHIBITS THE EARLY ATHEROSCLEROTIC LESIONS IN APO-E DEFICIENT MICE BY BLOCKING TP RECEPTORS AND THROMBOXANE SYNTHASE. In Congress of the International Society of Thrombosis and Hemostasis- 57th Annual SSC Meeting.

Hanson, J. (10 June 2011). Mechanism of Nicotinic acid-induced Flushing [Paper presentation]. GPCR Workshop, Utrecht, Netherlands.

Cherdon, C., Rolin, S., Hanson, J., OOMS, A., de Leval, L., Drion, P., Michiels, C., Pirotte, B., Masereel, B., SakalihasanN, N., DEFRAIGNE, J., & Dogné, J.-M. (2011). BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase. Prostaglandins and Other Lipid Mediators. doi:10.1016/j.prostaglandins.2011.03.001

Gilissen, J., Pirotte, B., & Hanson, J. (2011). Synthèse et évaluation pharmacologique de modulateurs du récepteur de l'acide succinique (SUCNR1) [Poster presentation]. 25e Journées franco-belges de pharmacochimie.

lukasova, M., Hanson, J., Tunaru, S., & Offermanns, S. (2011). Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials. Trends in Pharmacological Sciences. doi:10.1016/j.tips.2011.08.002

SEGERS, K., Hanson, J., RAMAEKERS, V., & Bours, V. (02 November 2010). Molecular analysis of the FOLR genes in patients with cerebral folate deficiency [Poster presentation]. 60° American Society of Human Genetics Meeting.

Hanson, J., Gille, A., Zwykiel, S., Lukasova, M., Clausen, B., Ahmed, K., Tunaru, S., Wirth, A., & Offermanns, S. (17 July 2010). Role of Keratinocytes GPR109A and COX-2 in Nicotinic Acid and Mono-methyl Fumarate Induced Flushing [Poster presentation]. 16th World Congress of Basic and Clinical Pharmacology, Copenhagen, Denmark.

Ahmed, K., Tunaru, S., Tang, C., Muller, M., Gille, A., Sassmann, A., Hanson, J., & Offermanns, S. (2010). An autocrine lactate loop mediates insulin-dependent inhibition of lipolysis through GPR81. Cell Metabolism, 11 (4), 311-9. doi:10.1016/j.cmet.2010.02.012

Hanson, J., Gille, A., Zwykiel, S., Lukasova, M., Clausen, B. E., Ahmed, K., Tunaru, S., Wirth, A., & Offermanns, S. (2010). Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. Journal of Clinical Investigation, 120 (8), 2910-9. doi:10.1172/JCI42273

Ahmed, K., Tunaru, S., Langhans, C. D., Hanson, J., Michalski, C. W., Kölker, S., Jones, P. M., Okun, J. G., & Offermanns, S. (2009). Deorphanization of GPR109B as a receptor for the beta-oxidation intermediate 3-OH-octanoic acid and its role in the regulation of lipolysis. Journal of Biological Chemistry, 284 (33), 21928-33. doi:10.1074/jbc.M109.019455

Cherdon, C., Rolin, S., Hanson, J., Drion, P., de Leval, L., Dogné, J.-M., & Defraigne, J.-O. (11 October 2007). Bm-573, an original thromboxane receptor antagonist, reduces development of atherosclerosis in apoe–deficient (apo e-/-) mice [Poster presentation]. Treizième forum des sciences pharamceutiques, Spa, Belgium.

Cherdon, C., Rolin, S., Hanson, J., Drion, P., de Leval, L., Defraigne, J.-O., & Dogné, J.-M. (22 June 2007). Bm-573, a thromboxane receptor antagonist, reduces development of atherosclerosis in apoe–deficient mice [Poster presentation]. FROM CELL TO MAN TO SOCIETY - XIX World Congress of the ISHR, Bologne, Italy.

Cherdon, C., Rolin, S., Hanson, J., Drion, P., de Leval, L., Defraigne, J.-O., & Dogné, J.-M. (10 May 2007). Le bm-573, un antagoniste original de récepteur au thromboxane a2, réduit le développement des lesions atheromateuses chez des souris deficientes en apolipoproteine e (apo e-/-) [Poster presentation]. 21ème Journées Franco-Belges de Pharmaco chimie, , Namur, Belgique, Namur, Belgium.

Moray, A. L., Dogne, J. M., Neven, P., Ghiotto, J., Pirotte, B., & Hanson, J. (May 2007). Conception et synthèse d’outils pharmacologiques originaux pour l’étude des récepteurs au thromboxane [Poster presentation]. 21èmes Journées Franco-Belges de Pharmacochimie, Namur, Belgium.

Cherdon, C., Rolin, S., Hanson, J., Drion, P., De Leval, L., Defraigne, J.-O., & Dogné, J.-M. (2007). BM-573, a thromboxane receptor antagonist, reduces development of atherosclerosis in apoE–deficient mice. Journal of Molecular and Cellular Cardiology, 42 (suppl 1.), 33-34. doi:10.1016/j.yjmcc.2007.03.095

Hanson, J. (2007). Design, synthesis and pharmacological evaluation of sulfonylureas and sulfonycyanoguanidines as thromboxane A2 receptor antagonists. Insights into selectivity between thromboxane A2 receptor isoforms (TPα et TPβ) [Doctoral thesis, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/77285

Hanson, J., Dogné, J.-M., Ghiotto, J., Moray, A.-L., Kinsella, B. T., & Pirotte, B. (2007). Design, synthesis, and SAR study of a series of N-alkyl-N'-[2-(aryloxy)-5-nitrobenzenesulfonyl]lureas and -cyanoguanidine as selective antagonists of the TPalpha and TPBeta isoforms of the human thromboxane A2 receptor. Journal of Medicinal Chemistry, 50, 3928-3936. doi:10.1021/jm070427h

Lanoye, L., Segers, P., Tchana-Sato, V., Rolin, S., Dogné, J.-M., Ghuysen, A., Lambermont, B., Hanson, J., Desaive, T., Verdonck, P., D'Orio, V., & Kolh, P. (01 January 2007). Cardiovascular haemodynamics and ventriculo-arterial coupling in an acute pig model of coronary ischaemia-reperfusion. Experimental Physiology, 92 (1), 127-137. doi:10.1113/expphysiol.2006.034983

Rolin, S.* , Hanson, J.* , Vastersaegher, C., Cherdon, C., Pratico, D., Masereel, B., & Dogné, J.-M. (2007). BM-520, an original TXA(2) modulator, inhibits the action of thromboxane A(2) and 8-iso-prostaglandin F-2 alpha in vitro and in vivo on human and rodent platelets, and aortic vascular smooth muscles from rodents. Prostaglandins and Other Lipid Mediators, 84 (1-2), 14-23. doi:10.1016/j.prostaglandins.2007.03.002
* These authors have contributed equally to this work.

Hanson, J., Dogne, J. M., Ghiotto, J., Moray, A. L., Neven, P., Kelley, L. P., Kinsella, B. T., & Pirotte, B. (18 November 2006). Pharmacological evaluation of TP receptor antagonists by differential activity on alpha and beta isoforms [Poster presentation]. Réunion de la Société Belge de Physiologie et de Pharmacologie Fondamentales et Cliniques, Bruxelles, Belgium.

Hanson, J., Dogne, J. M., Kelley, L. P., Kinsella, B. T., & Pirotte, B. (August 2006). Development of a fluorescent microplate cell based assay for the rapid evaluation of human thromboxane A2 receptor modulators acting on α and β isoforms [Poster presentation]. XIXth International Symposium on Medicinal Chemistry, Istanbul, Turkey.

Hanson, J., Ghiotto, J., Neven, P., Kelley, L. P., Kinsella, B. T., Dogne, J. M., & Pirotte, B. (July 2006). Pharmacological evaluation of TP receptor antagonists characterized by differential activity on alpha and beta isoforms. Acta Pharmacologica Sinica, 27, 21.

Cherdon, C., Hanson, J., Pirotte, B., Dogne, J. M., & Defraigne, J.-O. (June 2006). Activité préférentielle de la 8-iso-prostaglandine F2A (8-iso-PGF2A) sur l’isoforme alpha du récepteur au thromboxane A2 [Poster presentation]. 20èmes Journées Franco-Belges de Pharmacochimie, Lille, France.

Hanson, J., Dogne, J. M., Ghiotto, J., Kelley, L. P., Kinsella, B. T., & Pirotte, B. (June 2006). Evaluation pharmacologique d'une série de composés nitrobenzéniques sur les deux isoformes du récepteur au thromboxane A2, TPα et TPβ [Poster presentation]. 20èmes Journées Franco-Belges de Pharmacochimie, Lille, France.

Hanson, J., Reynaud, D., Qiao, N., Devel, P., Moray, A.-L., Renard, J.-F., Kelley, L. P., Winum, J.-Y., Montero, J.-L., Kinsella, B. T., Pirotte, B., Pace-Asciak, C. R., & Dogné, J.-M. (June 2006). Synthesis and pharmacological evaluation of novel thromboxane modulators as antiplatelet agents acting on both the alpha and beta isoforms of the human thromboxane receptor. Journal of Medicinal Chemistry, 49 (12), 3701-3709. doi:10.1021/jm060108a

Cherdon, C., Rolin, S., Hanson, J., Duwez, L., Drion, P., Pincemail, J., de Leval, L., Defraigne, J.-O., & Dogné, J.-M. (17 May 2006). The use of an apoE–deficient (apoE-/-) mice model to characterize the therapeutic benefits of original thromboxane modulators [Poster presentation]. Bioforum 2006, Liège, Belgique, Liège, Belgium.

Hanson, J., Dogne, J. M., Kelley, L. P., Kinsella, B. T., & Pirotte, B. (17 May 2006). Development of a fluorescent microplate cell based assay for the rapid evaluation of human thromboxane A2 receptor modulators acting on α and β isoforms [Poster presentation]. 10th Bioforum, Liège, Belgium.

Kolh, P., Rolin, S., Tchana-Sato, V., Petein, M., Ghuysen, A., Lambermont, B., Hanson, J., Magis, D., Segers, P., Masereel, B., D'Orio, V., & Dogné, J.-M. (March 2006). Evaluation of BM-573, a novel TXA(2) synthase inhibitor and receptor antagonist, in a porcine model of myocardial ischemia-reperfusion. Prostaglandins and Other Lipid Mediators, 79 (1-2), 53-73. doi:10.1016/j.prostaglandins.2005.10.002

Dogné, J.-M., Hanson, J., de Leval, X., Pratico, D., Pace-Asciak, C. R., Drion, P., Pirotte, B., & Ruan, K.-H. (2006). From the design to the clinical application of thromboxane modulators [letter to the editor]. Current Pharmaceutical Design, 12 (8), 903-923. doi:10.2174/138161206776055921

Tchana-Sato, V., Dogné, J.-M., Lambermont, B., Ghuysen, A., Magis, D., Morimont, P., Hanson, J., D'Orio, V., Limet, R., & Kolh, P. (December 2005). Effects of BM-573, a thromboxane A(2) modulator on systemic hemodynamics perturbations induced by U-46619 in the pig. Prostaglandins and Other Lipid Mediators, 78 (1-4), 82-95. doi:10.1016/j.prostaglandins.2005.04.001

Dogné, J.-M., Rolin, S., Tchana-Sato, V., Petein, M., Lambermont, B., Ghuysen, A., Hanson, J., & Kolh, P. (September 2005). Characterisation of an original model of myocardial infarction provoked by coronary artery thrombosis induced by ferric chloride in pig. European Heart Journal, 26 (Suppl. 1), 455-456.

Hanson, J., Reynaud, D., Qiao, N., Renard, J.-F., Botty, D., Neven, P., Pace-Asciak, C. R., Pirotte, B., & Dogne, J. M. (May 2005). Synthèse et évaluation pharmacologique de composés nitrobenzéniques originaux présentant des affinités différentielles pour les isoformes du récepteur au thromboxane A2 [Poster presentation]. 19èmes Journées Franco-Belges de Pharmacochimie, Liège, Belgium.

Kolh, P., Lambermont, B., Ghuysen, A., Tchana-Sato, V., Dogné, J.-M., Hanson, J., Gérard, P., D'Orio, V., Pierard, L., & Limet, R. (February 2005). Effects of dobutamine on left ventriculoarterial coupling and mechanical efficiency in acutely ischemic pigs. Journal of Cardiovascular Pharmacology, 45 (2), 144-152. doi:10.1097/01.fjc.0000151928.27273.02

Dogné, J.-M., Rolin, S., Petein, M., Tchana-Sato, V., Ghuysen, A., Lambermont, B., Hanson, J., Magis, D., Segers, P., Pirotte, B., Masereel, B., Drion, P., D'Orio, V., & Kolh, P. (2005). Characterization of an original model of myocardial infarction provoked by coronary artery thrombosis induced by ferric chloride in pig. Thrombosis Research, 116 (5), 431-442. doi:10.1016/j.thromres.2005.02.006

Ghuysen, A., Dogné, J.-M., Chiap, P., Rolin, S., Masereel, B., Lambermont, B., Kolh, P., Tchana-Sato, V., Hanson, J., & D'Orio, V. (2005). Pharmacological profile and therapeutic potential of BM-573, a combined thromboxane receptor antagonist and synthase inhibitor. Cardiovascular Drug Reviews, 23 (1), 1-14. doi:10.1111/j.1527-3466.2005.tb00153.x

Hanson, J., Rolin, S., Reynaud, D., Qiao, N., Kelley, L. P., Reid, H. M., Valentin, F., Tippins, J., Kinsella, B. T., Masereel, B., Pace-Asciak, C. R., Pirotte, B., & Dogné, J.-M. (2005). In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea]. Journal of Pharmacology and Experimental Therapeutics, 313, 293-301. doi:10.1124/jpet.104.079301

Lanoye, L., KOLH, P., Rolin, S., TCHANA-SATO, V., Dogné, J.-M., GHUYSEN, A., LAMBERMONT, B., Magis, D., Hanson, J., Segers, P., Gérard, P., Masereel, B., D'ORIO, V., & Limet, R. (2005). Effects of reperfusion on left ventricular hemodynamics and ventriculo-arterial coupling in acutely ischemic pigs. Computer Methods in Biomechanics and Biomedical Engineering, 8 (suppl. 1), 169-170.

Ghuysen, A., Lambermont, B., Dogné, J.-M., Kolh, P., Tchana-Sato, V., Morimont, P., Magis, D., Hanson, J., Segers, P., & D'Orio, V. (September 2004). Effect of BM-573[N-terbutyl-N '-[2-(4 '-methylphenylamino)-5-nitro-benzenesulfonyl] urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism. Journal of Pharmacology and Experimental Therapeutics, 310 (3), 964-972. doi:10.1124/jpet.104.066852

Hanson, J., Renard, J.-F., Neven, P., De Leval, X., Rolin, S., Pirotte, B., & Dogne, J. M. (June 2004). Synthèse et évaluation pharmacologique de nouveaux antagonistes du récepteur au thromboxane A2 dérivés du BM-573 [Poster presentation]. 18èmes Journées Franco-belges de Pharmacochimie, Luxembourg, Luxembourg.

De Leval, X., Dassesse, T., Benoit, V., Hanson, J., Dogne, J. M., Castronovo, V., & Pirotte, B. (May 2004). Development of thromboxane A2 modulators as promising anti-metastatic and anti-angiogenic compounds [Paper presentation]. 12th Forum of Pharmaceutical Sciences, Blankenberge, Belgium.

Hanson, J., Rolin, S., De Leval, X., Reynaud, D., Qiao, N., Neven, P., Masereel, B., Pace-Asciak, C. R., Pirotte, B., & Dogné, J.-M. (May 2004). In vivo evaluation of antithrombotic potency of BM-613, a thromboxane A2 receptor antagonist, in a rat model of arterial thrombosis [Paper presentation]. 12th Forum of Pharmaceutical Sciences, Blankenberge, Belgium.

De Leval, X., Hanson, J., David, J.-L., Masereel, B., Pirotte, B., & Dogné, J.-M. (2004). New developments on thromboxane and prostacyclin modulators. Part II: prostacyclin modulators. Current Medicinal Chemistry, 11, 1243-1252. doi:10.2174/0929867043365279

Dogné, J.-M., De leval, X., Hanson, J., Frederich, M., Lambermont, B., Ghuysen, A., Casini, A., Masereel, B., Ruan, K. E., Pirotte, B., & Kolh, P. (2004). New developments on thromboxane and prostacyclin modulators. Part I: thromboxane modulators. Current Medicinal Chemistry, 11, 1223-1241. doi:10.2174/0929867043365260

Dogné, J.-M., Hanson, J., De leval, X., Kolh, P., Tchana-Sato, V., de Leval, L., Rolin, S., Ghuysen, A., Segers, P., Lambermont, B., Masereel, B., & Pirotte, B. (2004). Pharmacological characterization of N-tert-butyl-N’-[2-(4’-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time. Journal of Pharmacology and Experimental Therapeutics, 309 (2), 498-505. doi:10.1124/jpet.103.063610

Dogné, J.-M., Hanson, J., De leval, X., Masereel, B., Kolh, P., & Pirotte, B. (2004). New developments on thromboxane modulators. Mini Reviews in Medicinal Chemistry, 649-657. doi:10.2174/1389557043403684

Hanson, J., De Leval, X., David, J.-L., Supuran, C., Pirotte, B., & Dogné, J.-M. (2004). Progress in the field of GPIIb/IIIa antagonists. Current Medicinal Chemistry - Cardiovascular and Hematological Agents, 2, 157-167. doi:10.2174/1568016043477224

Hanson, J., Kolh, P., Rolin, S., Tchana-Sato, V., De Leval, X., Petein, M., Masereel, B., Pirotte, B., Dogné, J.-M., Lambermont, B., David, J. L., & GHUYSEN, A. (2004). In vivo pharmacological evaluation of BM-573, an original thromboxane A2 receptor antagonist and thromboxane synthase inhibitor. Fundamental and Clinical Pharmacology, 270.

Hanson, J., Renard, J.-F., Neven, P., De leval, X., Rolin, S., Pirotte, B., & Dogné, J.-M. (2004). Synthésis and pharmacological evaluation of original thromboxane A2 receptor antagonists derived from BM-573. Fundamental and Clinical Pharmacology, 596.

Hanson, J., Rolin, S., De Leval, X., Neven, P., Masereel, B., Pirotte, B., & Dogné, J.-M. (2004). Characterization of preferential activity on platelet thromboxane A2 receptors of BM-613, a new thromboxane A2 antagonist. Fundamental and Clinical Pharmacology, 269.

Dogne, J. M., Kolh, P., Rolin, S., Tchana-Sato, V., Hanson, J., De Leval, X., Lambermont, B., Ghuysen, A., Petein, M., De Leval, X., Masereel, B., & Pirotte, B. (December 2003). Antithrombotic activity of BM-573, a novel thromboxane modulator, in rat arterial thrombosis model, pig myocardial infarction model and its effect on bleeding time [Poster presentation]. 45th ASH Annual Meeting, San Diego, United States.

Hanson, J., Rolin, S., De Leval, X., Neven, P., Masereel, B., Pirotte, B., & Dogne, J. M. (December 2003). BM-613, a new thromboxane A2 antagonist, is characterized by a preferential activity on platelet thromboxane A2 receptors [Poster presentation]. 45th ASH Annual Meeting, san Diego, United States.

Hanson, J., Rolin, S., De Leval, X., Neven, P., Masereel, B., Pirotte, B., & Dogne, J. M. (22 November 2003). BM-613, a new thromboxane A2 antagonist, is characterized by a preferential activity on platelet thromboxane A2 receptors [Poster presentation]. Réunion de la Société Belge de Physiologie et de Pharmacologie Fondamentales et Cliniques, Liège, Belgium.

Hanson, J., Kolh, P., Rolin, S., Tchana-Sato, V., De Leval, X., Lambermont, B., Ghuysen, A., Petein, M., Masereel, B., Pirotte, B., & Dogne, J. M. (November 2003). Antithrombotic activity of BM-573, a novel thromboxane modulator, in rat arterial thrombosis model, pig myocardial infarction model and its effects on bleeding time [Poster presentation]. Réunion de la Société Belge de Physiologie et de Pharmacologie Fondamentales et Cliniques, Liège, Belgium.

Hanson, J., Rolin, S., De Leval, X., Neven, P., Devel, P., Masereel, B., Pirotte, B., & Dogne, J. M. (May 2003). Synthesis and pharmacological evaluation of BM-613, an original thromboxane A2 antagonist [Poster presentation]. 11th Forum of pharmaceutical sciences, Spa, Belgium.

Hanson, J., Rolin, S., De Leval, X., Neven, P., Devel, P., Masereel, B., Pirotte, B., & Dogne, J. M. (May 2003). Pharmacological evaluation of the thromboxane A2 receptor antagonist BM-613 [Poster presentation]. XVIIèmes Journées Franco-Belges de Pharmacochimie, Woluwe-Saint-Lambert, Belgium.

Hanson, J., Rolin, S., De Leval, X., Neven, P., Devel, P., Masereel, B., Pirotte, B., & Dogne, J. M. (31 January 2003). Etude de la sélectivité tissulaire d’un nouvel antagoniste des récepteurs au thromboxane A2, le BM-613 [Poster presentation]. 10éme Journée Jeunes Chercheurs, Paris, France.

Dogné, J.-M., Kolh, P., Rolin, S., Tchana-Sato, V., Hanson, J., De Leval, X., Lambermont, B., Ghuysen, A., Petein, M., de Leval, L., Masereel, B., & Pirotte, B. (2003). Antithrombotic activity of BM-573, a novel thromboxane modulator, in rat arterial thrombosis model, pig myocardial infarction model and its effect on bleeding time. Blood, 106.

Hanson, J., De Leval, X., Kolh, P., Supuran, C., Pirotte, B., & Dogné, J.-M. (2003). Update on GPIIb/IIIa antagonists. Expert Opinion on Therapeutic Patents, 13, 1173-1188. doi:10.1517/13543776.13.8.1173

Hanson, J., Rolin, S., De Leval, X., Neven, P., De Leval, L., Masereel, B., Pirotte, B., & Dogné, J.-M. (2003). BM-613, a new thromboxane A2 antagonist, is characterized by a preferential activity on platelet thromboxane A2 receptors. Blood, 813a-814.